Webcast to be held Wednesday, February 11, 2026, at 8:00 a.m. ET –WALTHAM, Mass., Feb. 10, 2026 (GLOBE NEWSWIRE) -- Upstream Bio, Inc. (Nasdaq: UPB), a clinical-stage company developing treatments for ...

Statin use had a statistically significant protective effect against acute asthma exacerbations in mild asthma among Black ...

In December 2025, Cogent announced that the company submitted its New Drug Application for bezuclastinib in NonAdvSM to the U.S. Food and Drug Administration. The submission is based on positive ...

A new study published today in the Journal of the American Medical Association (JAMA) Pediatrics examines risk factors for developing food allergy. Researchers from the Asthma and Allergy Foundation ...

Generate Biomedicines’ IPO aims to fund Phase 3 GB-0895 for severe asthma/COPD and expand its pipeline. Learn more about GENB ...

Affecting approximately 262 million people worldwide, asthma is a chronic condition of the lungs that causes airway inflammation. 1. Typical symptoms include: Breathlessness; Whee ...

Patients with depressive symptoms and asthma had elevated levels of serum brain-derived neurotrophic factor in association ...

A grant-funded collaboration between El Centro Regional Medical Center (ECRMC) and the Imperial Valley Public Health Department is helping residents better manage asthma with the Asthma Wellness ...

Michigan researchers and doctors are improving asthma treatment with new therapies, addressing Detroit's high asthma burden.

Treatment with twice-yearly depemokimab resulted in a significant reduction in the rate of annualized asthma exacerbations compared with placebo. The Food and Drug Administration (FDA) has approved ...

Exdensur is the first and only ultra-long-acting biologic with twice-yearly dosing approved for patients with severe asthma with an eosinophilic phenotype Approval based on SWIFT trials showing ...